Acumen Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Acumen Pharmaceuticals

26/03/2024 13:32

* Acumen Pharmaceuticals Inc  ABOS.OQ  reported a quarterly
adjusted loss of 28 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -32 cents.  The mean expectation of
six analysts for the quarter was for a loss of 26 cents per
share. Wall Street expected results to range from -34 cents
to -20 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Acumen Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 28 cents​.
    * The company reported a quarterly loss of $16.38 million.
    * Acumen Pharmaceuticals Inc shares had risen by 10.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Acumen
Pharmaceuticals Inc is $14.50 
This summary was machine generated from LSEG data March 26 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.26          -0.28          Missed
 Sep. 30 2023      -0.27          -0.24          Beat
 Jun. 30 2023      -0.35          -0.28          Beat
 Mar. 31 2023      -0.35          -0.28          Beat